A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
Charlotte Benson(Cancer Research UK), Chris Twelves(Beatson West of Scotland Cancer Centre)
Cited by 257
Related Papers
Cellular Uptake and Efflux of Palbociclib In Vitro in Single Cell and Spheroid Models
|Journal of Pharmacology and Experimental Therapeutics|2019|11